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Abstract
Severe a1-antitrypsin deficiency results from the Z allele
(Glu342Lys) that causes the accumulation of homopolymers of
mutant a1-antitrypsin within the endoplasmic reticulum of hepa-
tocytes in association with liver disease. We have used a DNA-
encoded chemical library to undertake a high-throughput screen
to identify small molecules that bind to, and stabilise Z a1-antit-
rypsin. The lead compound blocks Z a1-antitrypsin polymerisation
in vitro, reduces intracellular polymerisation and increases the
secretion of Z a1-antitrypsin threefold in an iPSC model of disease.
Crystallographic and biophysical analyses demonstrate that
GSK716 and related molecules bind to a cryptic binding pocket,
negate the local effects of the Z mutation and stabilise the bound
state against progression along the polymerisation pathway. Oral
dosing of transgenic mice at 100 mg/kg three times a day for
20 days increased the secretion of Z a1-antitrypsin into the plasma
by sevenfold. There was no observable clearance of hepatic inclu-
sions with respect to controls over the same time period. This
study provides proof of principle that “mutation ameliorating”
small molecules can block the aberrant polymerisation that under-
lies Z a1-antitrypsin deficiency.
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Introduction
Alpha-1 antitrypsin deficiency affects 1 in 2,000 people of Northern
European descent, leading to liver and lung diseases (Lomas et al,
2016). Ninety-five per cent of severe deficiency results from the “Z”
allele (Glu342Lys) that perturbs the folding of a1-antitrypsin result-
ing in the secretion of only 15% of the mature protein. The remain-
ing protein is retained within the cell by persistent binding to
molecular chaperones (Wu et al, 2003) and then either degraded via
the ERAD-proteasome pathway (Le et al, 1992; Qu et al, 1996; Teck-
man et al, 2001) or folded into ordered polymers that may be
cleared by autophagy (Teckman et al, 2004) or accumulate within
the endoplasmic reticulum (ER) of hepatocytes (Lomas et al, 1992).
The accumulation of polymers causes neonatal hepatitis, cirrhosis
and hepatocellular carcinoma, and can sensitise the liver to damage
from environmental insults such as alcohol, fat or viral hepatitis
(Ordo~nez et al, 2013; Strnad et al, 2019). The consequent deficiency
of a1-antitrypsin within the circulation results in insufficient protec-
tion of the lungs from neutrophil elastase, leading to early-onset
emphysema (Lomas et al, 2016).
The Z mutation lies at the head of strand 5 of b-sheet A of a1-
antitrypsin. It perturbs the local environment, allowing population
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of an unstable intermediate that we have termed M* (Dafforn et al,
1999) in which b-sheet A opens and the upper part of helix F
unwinds (Gooptu et al, 2000; Nyon et al, 2012). Polymerisation
from this state involves insertion of the RCL into b-sheet A with a
domain-swap of the C-terminal region providing the inter-subunit
linkage (Huang et al, 2016; Faull et al, 2020; Laffranchi et al, 2020).
The resulting polymer is deposited within hepatocytes.
The aim of our work was to develop a small molecule corrector
of Z a1-antitrypsin folding that was able to block the formation of
polymers within the ER of hepatocytes and that was suitable for oral
dosing as a potential treatment for a1-antitrypsin deficiency. To
achieve this, we needed to overcome a number of challenges: (i) the
drug target is a highly mobile folding intermediate located in the ER;
(ii) disparity in the size of the interface between a small molecule
and the large protein–protein interaction that it is designed to block;
(iii) oral dosing greatly restricts suitable chemical space; (iv) as a
non-classical drug target, small molecule binders may well not be
well-represented in compound screening libraries; and (v) the rela-
tively high concentration of circulating monomeric Z a1-antitrypsin
(~ 5 lM), even in individuals with severe plasma deficiency, repre-
sents a high-affinity sink for compound, restricting its access to the
target in the hepatocyte and requiring high total blood concentra-
tions of drug to achieve sufficient free drug concentration and target
engagement in the liver.
Results
Identification of GSK716 through encoded library technology
screening, structure-guided drug design and cellular profiling
Z a1-antitrypsin is a conformationally dynamic molecule (Lomas
et al, 1992; Knaupp et al, 2010) that represents a non-classical target
for drug discovery. A cell-free assay approach to hit finding was
undertaken so as not to miss compounds that bind a1-antitrypsin
and block polymerisation but lack the molecular properties to cross
cell membranes. This comprised the following: (i) an encoded
library technology (ELT) screen (Goodnow et al, 2017) of a library
with a nominal diversity of 2 × 1012 unique components to identify
binders to Z a1-antitrypsin and (ii) a high-throughput screen (HTS)
of the GSK compound collection (~ 1.7 million compounds) for
small molecules that could block polymerisation of Z a1-antitrypsin.
In both screening approaches, glycosylated Z a1-antitrypsin, purified
from the plasma of Z a1-antitrypsin homozygotes (Lomas et al,
1993), was used since this represents the disease-relevant human
pathophysiological drug target that populates an intermediate on the
polymerisation pathway (Knaupp et al, 2010; Irving et al, 2015).
ELT selections were performed by incubating Z a1-antitrypsin with
DNA-encoded compound libraries for 1 h at 4 and 37°C for three
rounds of selection with subsequent capture of Z a1-antitrypsin
using a1-antitrypsin select resin (GE Healthcare). A variation on this
protocol using pre-immobilised Z a1-antitrypsin was also used for
library selections. In the HTS assay, polymerisation of purified Z a1-
antitrypsin was induced by incubation at 37°C for 72 h in the pres-
ence of test compounds, with end-point quantification of polymers
performed using the polymer-specific monoclonal antibody, 2C1
(Miranda et al, 2010) in a TR-FRET-based immunoassay. A
number of small molecules that could block polymerisation of
Z a1-antitrypsin were obtained through the HTS but none progressed
beyond the early lead optimisation stage. However, a single lead
series of chiral hydroxy-carboxamides (GSK425) was identified from
the ELT screen that also demonstrated functional activity at block-
ing polymerisation in the TR-FRET immunoassay (pIC50 6.5; Fig 1A
and B).
Optimisation of this initial hit followed a structure-based design
approach, exploiting knowledge from iterative crystal structures of
small molecule ligands complexed with a1-antitrypsin. The central
hydroxy carboxamide and propyl chain were found to be critical for
binding to Z a1-antitrypsin and hence further medicinal chemistry
development focussed on modification of the phenyl and indole
heterocycle. This resulted in an ~ 100-fold increase in potency and
the discovery of the 2-oxindole GSK716 (pIC50 8.3; Fig 1A and B).
GSK716 is a potent inhibitor of polymerisation in vitro and in cell
models of disease
GSK716 binds to Z a1-antitrypsin with a high-affinity mean pKD
8.5  0.12 (n = 18) as determined by a competition binding assay
with a fluorescently labelled derivative (Fig 1C). The binding
demonstrates selectivity with a 50-fold lower affinity for plasma-
purified wild-type M a1-antitrypsin at mean pKD 6.8  0.18
(n = 10; Fig 1C). The shape of the curves and native mass spec-
trometry (not shown) are consistent with a single high-affinity
compound binding site. No binding of the fluorescent derivative to
polymers of Z a1-antitrypsin was observed, indicating conforma-
tional selectivity for the monomeric protein (Fig 1D). The rate of
interaction of the compound with the target was monitored through
changes in intrinsic tryptophan fluorescence (Dafforn et al, 1999);
this property was used to determine the second-order association
rate constants for GSK716 binding to Z (4.1 × 104 M1 s1) and
M a1-antitrypsin (2.1 × 10
2 M1 s1; Fig 1E and F). From the
association rate constants and the affinity values, first-order dissoci-
ation rate constants were calculated and found to be of the same
order of magnitude for Z (6.1 × 105 s1) and M a1-antitrypsin
(1.6 × 105 s1). Therefore, the selectivity of the compound for Z
over M a1-antitrypsin is dominated by the difference in the rate of
association rather than dissociation.
The ability of GSK716 to block Z a1-antitrypsin polymerisation in
the ER during folding was assessed by adding GSK716 to CHO-TET-
ON-Z-A1AT cells (Ordo~nez et al, 2013) with simultaneous induction
of Z a1-antitrypsin expression using doxycycline. In comparison
with controls, GSK716 completely blocked the intracellular forma-
tion of Z a1-antitrypsin polymers, as measured by staining with the
2C1 anti-Z a1-antitrypsin polymer monoclonal antibody (mean
pIC50 = 6.3  0.23; n = 71; Fig 2A and B). It also increased the
secretion of Z a1-antitrypsin (mean pEC50 6.2  0.23; n = 74;
Fig 2B). Similar potency between the effects on secretion and poly-
merisation was observed throughout members of the lead series
supporting the hypothesis that these effects are caused by the same
pharmacological mode of action. GSK716 had a similar effect on the
secretion and polymerisation of constitutively expressed Z a1-antit-
rypsin in iPSC-derived human hepatocytes with the ZZ a1-antit-
rypsin genotype (Yusa et al, 2011). It inhibited polymerisation and
increased secretion with a mean pIC50 of 6.4  0.45 (n = 16) and
mean pEC50 of 6.5  0.37 (n = 14), respectively, inducing an
approximately threefold increase in secreted levels of Z a1-antitrypsin
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(Fig 2C and D). GSK716 treatment reduced the levels of intracellular
Z a1-antitrypsin polymer compared with cells assessed before
compound addition (Fig 2C), demonstrating that polymers can
be cleared over the time course of the experiment, and that
accumulation of polymers is reversible in ZZ-iPSC hepatocytes.
The pre-treatment of CHO cells induced to express Z a1-antit-
rypsin with GSK716 significantly reduced the formation of soluble
and insoluble polymers (Fig 2E; compare PRE with time 0). To
investigate the ability of GSK716 to protect cells from sensitisation
to a secondary insult, Z a1-antitrypsin expression was induced in
CHO-TET-ON-Z-A1AT cells in the presence or absence of 10 lM
GSK716 before exposure to increasing concentrations of the ER
stressor tunicamycin (Ordo~nez et al, 2013). Cells expressing wild-
type M a1-antitrypsin were less susceptible to tunicamycin toxicity
than cells expressing Z a1-antitrypsin in a cell viability assay
(Fig 2F). GSK716 restored sensitivity of Z a1-antitrypsin expressing
cells to that of the wild-type control cells. The effect of GSK716 on Z
a1-antitrypsin was confirmed in pulse-chase experiments (Fig 2G
and H).
These data collectively show that the small molecule completely
blocks the intracellular polymerisation of Z a1-antitrypsin and
increases secretion of the monomeric protein.
GSK716 binds to a novel cryptic binding site
A high-resolution crystal structure of a1-antitrypsin complexed with
the lead compound GSK716 was generated by soaking compound
into apo a1-antitrypsin crystals (Table 1). The structure reveals that
interaction with the compound induces the formation of a cryptic
binding site that is not evident in apo structures, at the top of b-
sheet A behind strand 5. This region is referred to as the “breach”
as it is the point at which the reactive centre loop first inserts during
protease inhibition (Whisstock et al, 2000), and includes the site of
the Z (Glu342Lys) mutation (Fig 3A). The structure reveals that the
2-oxindole ring of GSK716 stacks with the side chain of Trp194
whilst the carbonyl group forms a hydrogen bond with the main-
chain Trp194 (Fig 3B). Trp194 adopts a new position due to rear-
rangement of residues Gly192 to Thr203 consistent with the change
A B C
D E F
Figure 1. Characteristics of the lead series of chiral hydroxy-carboxamides identified from the ELT screen.
A The structure of GSK425, identified from the ELT screen, and the derived compound GSK716 obtained through a structure-based design pipeline.
B The degree of polymerisation of Z a1-antitrypsin after 72 h at 37°C, as determined by an end-point immunoassay using the 2C1 monoclonal antibody, in varying
concentrations of compound (shown in panel A). Modification of the phenyl and indole heterocycle of GSK425 (pIC50 6.5) resulted in an ~ 100-fold increase in
potency and the discovery of the 2-oxindole GSK716 (pIC50 8.3). Data presented as mean  SD, n = 2 (GSK425) and n = 25 (GSK716).
C GSK716 binds to Z a1-antitrypsin with a high-affinity mean pKD of 8.5  0.12 (n = 18) as determined by a competition binding assay with a fluorescently
labelled derivative. There was a 50-fold lower affinity for plasma-purified wild-type M a1-antitrypsin, with a mean pKD of 6.8  0.18 (n = 10). Data
presented as mean  SD.
D The compound bound to monomeric but not polymeric Z a1-antitrypsin (Z a1-AT) as reported by fluorescence polarisation of an Alexa-488-labelled variant of GSK716.
E Representative curves reporting the interaction of different concentrations of GSK716 with Z a1-antitrypsin based on changes in intrinsic tryptophan fluorescence.
Based on the concentration dependence (inset), the second-order rate constant of association was found to be 4.1 × 104 M1 s1.
F The association of GSK716 with M a1-antitrypsin, giving a second-order rate constant of 2.1 × 10
2 M1 s1.
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in intrinsic tryptophan fluorescence induced by binding (Fig 3C).
The phenyl ring and the propyl chain occupy two highly hydropho-
bic pockets (Fig 3D–G). Hydrogen bonds are formed between the
GSK716 hydroxyl group and the Leu291 backbone, the amide nitro-
gen hydrogen and the backbone carbonyl oxygen of Pro289, and
between the amide carbonyl and the Tyr 244 hydroxyl group
(Fig 3B). This causes displacement of residues Thr339 to Ser 359 of
strand 5A relative to the apoprotein. Few changes are seen outside
of these regions.
GSK716 interferes with the transition through the
polymerisation-prone intermediate M* by stabilising b-sheet A
Polymerisation of a1-antitrypsin involves transition through a tran-
sient intermediate state known as M*, that is readily populated by
the Z variant (Dafforn et al, 1999; Knaupp et al, 2010). The M*
conformational ensemble appears to be a distinct species between
the native state conformation and that of the final polymer. One of
the hallmarks of M* is its recognition by environment-sensitive
fluorescent reporter dyes. Thermal shift assays that make use of the
dye SYPRO Orange report the stability of the protein native state
against heat-induced unfolding. Experiments, performed using dif-
ferent temperature gradients in the presence and absence of 50lM
GSK716, demonstrated a marked increase in the transition midpoint
temperature (Fig 4A), consistent with the stabilisation of either or
both of the ground- and M*-states of a1-antitrypsin (Irving et al,
2014). Correspondingly, in a constant-temperature experiment,
oligomers were generated at higher temperatures in the presence of
the compound than in its absence when visualised by non-denatur-
ing PAGE (Fig 4B). Native state stability can also be probed by equi-
librium unfolding using chemical denaturants, where a peak in bis-
ANS fluorescence corresponds with a maximally populated unfold-
ing intermediate (James & Bottomley, 1998). The profiles in Fig 4C
show that for guanidinium hydrochloride-induced unfolding, this
point occurs at a considerably higher denaturant concentration
(~ 1.9 M) in the presence of 50 µM GSK716, than in its absence
(~ 1.3 M), reflecting an increase in the stability of the native-like
state with respect to an unfolding intermediate. The associa-
tion of GSK716 induced a marked quenching and blue-shift of
the a1-antitrypsin intrinsic tryptophan fluorescence spectrum
(Fig 4D, inset). The rate of change in fluorescence during associa-
tion of 10µM GSK716 was proportional to the propensity of
a1-antitrypsin mutants to form polymers in vivo: inert (M), mild
(S), moderate (Baghdad) and severe (Z) a1-antitrypsin (Fig 4D, top
and bottom).
To investigate whether this activity was consistent with action as
a chemical chaperone, M a1-antitrypsin and Z a1-antitrypsin were
unfolded in vitro into 6 M guanidine hydrochloride and rapidly
refolded by snap dilution into denaturant-free buffer in the presence
or absence of GSK716. Electrophoresis of the products by non-dena-
turing PAGE showed an anodally shifted migration for the Z variant
in the absence of compound (Fig 4E) consistent with a misfolded
by-product of M* (Ekeowa et al, 2010), which was corrected at stoi-
chiometric concentrations and above.
Mutations that interfere with the opening of b-sheet A or that
perturb its interaction with the N-terminal portion of the reactive
centre loop alter the ability of serpins to inhibit target proteases
(Hood et al, 1994; Irving et al, 2014). The stoichiometry of
inhibition (SI) was determined for M a1-antitrypsin and Z
a1-antitrypsin in discontinuous experiments against a model
target protease, chymotrypsin. The pre-incubation of both vari-
ants with GSK716 led to a > 98% loss of protease inhibitory
activity (Fig 5A). Resolution of the products of the interaction by
SDS–PAGE showed full cleavage of the reactive centre loop
(Fig 5B); therefore, this is not a consequence of the protease
recognition site in the reactive centre loop becoming inaccessible
to the enzyme. These data are consistent with a mechanism in
which the compound stabilises b-sheet A against conformational
change that mediates both inhibitory activity and pathological
misfolding.
◀ Figure 2. GSK716 inhibits polymerisation of Z a1-antitrypsin in cell models of disease.
A GSK716 was added to CHO-TET-ON-Z-A1AT cells (Ordo~nez et al, 2013) with simultaneous induction of Z a1-antitrypsin expression using doxycycline, and polymer
load was quantified with the 2C1 monoclonal antibody that is specific to pathological polymers of a1-antitrypsin (Miranda et al, 2010). The parent cell line that did
not express Z a1-antitrypsin provided a negative control. GSK716 completely prevented intracellular polymer formation. Scale bar: 50 µm.
B Quantification of immunostained CHO-TET-ON-Z-A1AT cells showed that GSK716 reduced intracellular polymer formation and increased the secretion of Z a1-
antitrypsin in a dose-dependent manner with similar potencies. Data were normalised to vehicle and a control compound from the GSK716 series at saturating
concentration. Data presented as mean  SD, n = 61 (secretion) and n = 67 (polymer inhibition).
C, D GSK716 was (C) administered to iPSC-derived-hepatocytes and (D) inhibited polymerisation and increased secretion with a similar potency. It induced an
approximately threefold increase in secreted levels of Z a1-antitrypsin compared with vehicle control. This was apparent even after polymers had been allowed to
form. Scale bar: 100 µm. Data presented as mean  SD, n = 8 (secretion) and n = 6 (polymer inhibition).
E CHO tetracycline-inducible cells expressing Z a1-antitrypsin were induced with 0.5 lg/ml doxycycline for 48 h and treated with 10 lM GSK716. Cells were then
lysed in 1% v/v NP-40 buffer at different time points (0, 12, 24, 36, 48, 60, 72, 84, 96 and 108 h). For every time point, NP-40-soluble and NP-40-insoluble fractions
were separated and immunoprecipitated with the 2C1 mAb and resolved by 4–12% w/v SDS–PAGE and a1-antitrypsin detected by immunoblotting. PRE indicates
cells pre-treated for 48 h with 10 lM GSK716 and induced for the same time with 0.5 lg/ml doxycycline. The rate of clearance of soluble and insoluble polymer is
shown.
F CHO-inducible cells expressing either wild-type M or Z a1-antitrypsin were induced with 0.5 lg/ml doxycycline and treated with 10 lM GSK716 or with 0.1%
DMSO vehicle (NT, not treated). After induction for 48 h, cells were treated with various doses of tunicamycin for 36 h. Cell viability was measured by Cell Counting
Kit-8. The results are shown as mean  SEM, n = 4.
G CHO-K1 Tet-On cells expressing Z a1-antitrypsin were induced with doxycycline (0.5 lg/ml) for 48 h. Cells were incubated with 10 lM GSK716 (or 0.1% v/v DMSO
for the control) during the induction. Culture media containing either the experimental compound or DMSO were changed every 24 h. After the induction, cells
were labelled for 10 min with 35S Met/Cys and chased at the indicated times. Culture media were collected and cells lysed in 1% v/v NP-40 buffer. Intracellular
fractions and culture media from cells expressing Z a1-antitrypsin were immunoprecipitated either with a mAb against total a1-antitrypsin (3C11) or with a
polymer-specific mAb (2C1). Samples were resolved by 4–12% w/v acrylamide SDS–PAGE and detected by autoradiography.
H The graphs show the effect of GSK716 on intracellular and extracellular Z a1-antitrypsin (mean  SEM, n = 2).
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Characterisation of drug-like properties of GSK716
GSK716 selectivity and PK properties were profiled in order to inves-
tigate the suitability of GSK716 for progression into in vivo studies
and the potential for taking it forward as a clinical candidate for test-
ing in humans. Since GSK716 results in loss of inhibitory activity of
a1-antitrypsin, the effect of the compound was assessed on other
closely related serpins. GSK716 did not affect the inhibitory activity
of antithrombin, neuroserpin and a1-antichymotrypsin towards their
cognate proteases (Fig 5C). Furthermore, there were no off-target
effects in a panel of assays considered predictive of known safety
liabilities that precluded further development of GSK716
(Table EV1).
Since GSK716 exhibited a good level of selectivity over the off-
target panel and over other serpins, we determined the in vitro
and in vivo PK properties of the molecule with a view to exploring
target engagement in vivo. GSK716 has a measured ChromLogD
(pH7.4) of 3.8, low binding to human serum albumin (84.2%) and
good solubility of amorphous drug substance in FaSSIF (969 lg/
ml). Permeability in MDR1-MDCK cells in the presence of pgp inhi-
bitor GF120918 was high at 248 and 240 nm/s for the apical to
basal and basal to apical directions, respectively (N53531-23 for
DI). GSK716 exhibited low metabolic clearance in human hepato-
cytes (0.31 ml/min/g tissue), with moderate to high clearance in
mouse hepatocytes (4.56 ml/min/g tissue). It exhibited weak time-
dependent inhibition of CYP3A4 resulting in a 1.59-fold shift in
IC50. Taken together, oral bioavailability is predicted to be high in
humans, with measured F in rat (48%) and dog (71%) at ≤ 3 mg/
kg being consistent with 100% absorption and losses via first-pass
metabolism only. Mean exposure of GSK716 in blood in the male
CD-1 mouse increased with dose following single PO administra-
tion at 10, 30 or 100 mg/kg (mean dose-normalised Cmax 58 
112, 113  27 and 113  27; DNAUCinf 202  101, 294  47 and
403  246, respectively).
GSK716 increases secretion of Z a1-antitrypsin in a transgenic
mouse model of Z a1-antitrypsin deficiency
GSK716 was evaluated in a transgenic mouse model with an engi-
neered random insertion of the human Z a1-antitrypsin gene (Teck-
man et al, 2004). Younger hemizygous, rather than older mice, were
selected as our longevity studies showed that circulating levels of Z
a1-antitrypsin increase with age (to levels much higher than seen in
patients) and these artificially high levels may act as a high-affinity
sink sequestering drug and preventing bioavailability at the site of
action in the liver. Further, older mice have larger a1-antitrypsin
inclusions that may be more difficult to reverse and any changes
would be more difficult to detect than in younger animals. The PK-
PD relationship of GSK716 was explored by dosing Z a1-antitrypsin
transgenic animals with 10, 30 or 100 mg/kg GSK716 three times a
day. Blood and liver were harvested on day 6 at 3 h (~ Cmax) and
8 h (Cmin) after the dose for the measurement of total and free drug
in both tissues. Blood was also harvested for the measurement of
monomeric Z a1-antitrypsin in plasma. Total concentrations of
GSK716 were determined by LC-MS/MS, and the free drug in both
tissues was determined using equilibrium dialysis to determine free
fraction in the samples, subsequently used to derive unbound
concentrations. Blood concentrations demonstrated that the Cmin
levels of free drug were at or above 300 nM, the cellular secretion
assay EC50, for the majority of the dosing period following 100 mg/
kg dosing, whereas 30 and 10 mg/kg doses resulted in free drug
levels in blood significantly below the cellular EC50 concentrations
for a large part of the dosing period. Both free and total drug
concentrations of GSK716 at the targeted site of action in the liver
were equivalent to those in blood (Table 2).
A significant fraction of the total Z a1-antitrypsin in the circula-
tion is in the polymeric conformation (Tan et al, 2014). There are
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no antibodies that are specific for monomeric Z a1-antitrypsin and
so to directly determine its concentration, a deconvolution method
was developed based on immunoassays with antibodies for either
total or polymeric a1-antitrypsin, and calibration curves with puri-
fied monomeric and polymeric Z a1-antitrypsin. Monomeric Z a1-
antitrypsin was measured in plasma samples following 6 days of
dosing, and levels were normalised to each animals’ pre-dose
control levels to account for the natural variation of Z a1-antitrypsin
between animals. Administration of 100 mg/kg GSK716 resulted in
a mean sevenfold increase in circulating monomeric Z a1-antitrypsin
levels demonstrating robust target engagement in the liver (Fig 6A).
Interestingly, 30 and 10 mg/kg groups also gave significant, dose-
dependent increases in circulating Z a1-antitrypsin despite free
concentrations being below the cellular EC50 for secretion for much
or all of the dosing period. Total drug levels and changes in Z a1-
antitrypsin following 3 days of dosing were indistinguishable from
those following 6 days of dosing. There was no effect on circulating
serum albumin after 5 days of dosing which provides evidence that
GSK716 is specific for Z a1-antitrypsin. Moreover, the effects are not
mediated by metabolites of GSK716 as the major metabolites have
much reduced or no binding to a1-antitrypsin.
Since GSK716 blocks polymer formation in cells, we explored the
effect of dosing GSK716 on liver polymer levels. Z a1-antitrypsin
polymers formed in CHO-TET-ON-Z-A1AT and ZZ-iPSC hepatocytes
are cleared from cells with a half-life of between 8 and 48 h depend-
ing on whether they partition to the soluble or insoluble fractions
(Ronzoni et al, 2020). Since the compound does not bind Z a1-antit-
rypsin polymer, an effect on total liver polymer levels will be depen-
dent on the rate at which the liver can clear the polymer already
present and the rate at which polymer continues to accumulate in
animals not treated with drug. GSK716 was dosed at 100 mg/kg
three times a day for 20 days. Monomeric Z a1-antitrypsin increased
by a mean of sevenfold to eightfold in plasma samples over the pre-
dosing baseline levels on days 15 and 21 of dosing, similar to the
effect in animals dosed for 3 or 6 days and consistent with sustained
target engagement through the dosing period (Fig 6A). Liver poly-
mer levels were investigated by staining with 2C1 anti-polymer
monoclonal antibody and were scored blind by a pathologist or by
quantification using an algorithm to measure all areas of positive
staining (Fig EV1). There was no difference observed in total liver
polymer load when assessed by manual or quantitative scoring
(Fig 6B and C). There was no significant fibrosis in any of the liver
sections. Intrahepatic a1-antitrypsin was also assessed by ELISA.
The vast majority (95–100%) of a1-antitrypsin within the liver was
polymer with the monomer typically being below the level of detec-
tion. Treatment with GSK716 increased the monomer measured in








Figure 3. GSK716 binds to a novel cryptic binding site.
A Cartoon representation of a1-antitrypsin with GSK716 shown in yellow stick format. The five-stranded b-A sheet is in blue.
B Interactions of GSK716 within the cryptic site with key residues shown in stick format and hydrogen bonds in black dashed lines.
C Overlay of ribbon representation of protein chains of GSK716 complex (green) with apoprotein (purple; PDB id 2QUG (Pearce et al, 2008)) showing the altered position
of Trp194 (stick format) that induces a change in conformation of the Gly192-to-Thr203 loop and re-orientation of Tyr244 (stick format).
D Surface representation of a1-antitrypsin to show propyl and phenyl pocket.
E Surface representation of a1-antitrypsin to show protein-ligand complement of the substituted phenyl and 2-oxindole rings.
F Fo-Fc omit density difference map for the ligand contoured at 3 sigma (red denotes negative, and blue denotes positive difference).
G Representative 2Fo-Fc electron density map contoured at 1.0 sigma around the ligand.
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◀ Figure 4. Stabilisation of a1-antitrypsin by GSK716.
A A SYPRO orange-based thermal stability assay, which reports the transition of M a1-antitrypsin and Z a1-antitrypsin from the native to an intermediate state over a
1°C/min thermal ramp, in the presence and absence of 50µM GSK716.
B M (above) and Z (below) a1-antitrypsin, at a concentration of 0.2 mg/ml in PBS + 5% v/v glycerol, were heated at a range of temperatures between 48 and 65°C for
4 h in the presence and absence of GSK716, as indicated. The oligomerisation state was determined by non-denaturing PAGE electrophoresis; the lane denoted “M”
contains the unheated monomeric control.
C M a1-antitrypsin and Z a1-antitrypsin were subjected to equilibrium unfolding into different concentrations of guanidine hydrochloride (gdnhcl) in the presence and
absence of GSK716, with bis-ANS dye added to report the presence of the unfolded intermediate. The normalised fluorescence intensity data were fitted with an
equation describing a three-state unfolding curve. Values shown are the mean of three independent experiments, and the error bars represent  SEM.
D Top panel, the association of GSK716 induced a marked quenching and blue-shift of the a1-antitrypsin intrinsic tryptophan fluorescence spectrum with respect to
unbound protein (inset graph). The association of 10 µM GSK716 with four a1-antitrypsin variants that vary in their propensity to polymerise, ranging from inert (M),
to mild (S), moderate (Baghdad denoted “B”) and severe (Z). Representative progress curves of the change in intrinsic tryptophan fluorescence at 330 nm for 0.2 mg/
ml protein are shown. Bottom panel, the half-time of association calculated from three such independent experiments (error bars are  SEM) show a correspondence
with the polymerisation propensity of the four variants. The change in Z a1-antitrypsin fluorescence was faster than the dead-time of the apparatus (~ 10 s), and
scaling was with reference to unbound intensity.
E Non-denaturing PAGE characterisation of the conformational state of M a1-antitrypsin and Z a1-antitrypsin, after rapidly refolding by snap dilution from 6M urea in
the presence or absence of GSK716 at the molar ratios indicated. The migration of polymers (pol) and monomers (mon) is shown. Arrows indicate the misfolded by-
product M* arising at sub-stoichiometric concentrations of compound.
A C
B
Figure 5. The effect of GSK716 on serpin inhibitory activity.
A a1-Antitrypsin was incubated at varying molar ratios with the model protease bovine a-chymotrypsin, and the residual protease activity determined. The intercept of
the regression with the abscissa reflects the number of molecules of a1-antitrypsin required to inhibit one molecule of chymotrypsin in the presence (+c) and absence
(c) of 50µM GSK716. Error bars reflect  SEM of three independent experiments.
B M a1-antitrypsin was incubated with different molar ratios of chymotrypsin and resolved by SDS–PAGE. The position of covalent a1-antitrypsin-chymotrypsin complex
(cpx), native (nat) and cleaved (clv) is shown.
C The inhibitory activity of a1-antichymotrypsin against chymotrypsin (ach + chym), neuroserpin against trypsin (neus + tryp), and antithrombin against thrombin
(atiii + thrombin) was determined in the presence and absence of GSK716. Error bars reflect  SD of two independent experiments.
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Discussion
Disrupting protein–protein interactions with small molecule
compounds that maintain drug-like properties is a significant chal-
lenge. Here, we describe the identification of a potent and selective
a1-antitrypsin corrector, GSK716 that abolishes intracellular poly-
merisation of Z a1-antitrypsin and increases the circulating levels of
monomeric protein by sevenfold in a transgenic mouse model of
disease. The co-crystal structure with a1-antitrypsin demonstrates
that the small molecule ameliorates the effect of the Glu342Lys (Z)
mutation by: (i) optimisation of hydrophobic packing in the breach
region; (ii) formation of hydrogen bonds with buried polar atoms;
and (iii) displacement of the backbone at the top of strand 5A into a
configuration less compatible with partial loop insertion. This move-
ment of strand 5A is an early step in reactive loop-b-sheet A models
of polymerisation (Gooptu et al, 2000) and an obligate one in the C-
terminal polymer linkage (Yamasaki et al, 2011). Following GSK716
binding, there is a marked stabilisation of a1-antitrypsin against the
conformational changes associated with M* intermediate formation.
This in turn increases folding efficiency, thereby reducing the forma-
tion of polymers. Precedent for this general mechanism comes from
our development of a tool monoclonal antibody that exerted a simi-
lar effect on Z a1-antitrypsin (Ordo~nez et al, 2015; Motamedi-Shad
et al, 2016).
The GSK716-associated displacement at the top of strand 5A is
consistent with the association rate-driven preference for Z a1-antitrypsin
and an increased availability of the cryptic pocket. The pocket, once
formed, appears to be structurally equivalent in both wild-type M and
mutant Z a1-antitrypsin, as reflected by a similar rate of dissociation of
GSK716. Binding of GSK716 to a1-antitrypsin increased with the propen-
sity of mutants to form polymers (M < S < Baghdad < Z a1-antitrypsin),
indicating that pocket formation and polymerisation are intimately
linked. GSK716 stabilises the partially folded a1-antitrypsin or the fully
folded but labile aberrant native form. This mode of action is compatible
with the lack of binding of GSK716 to polymers, in which partial or
complete insertion of the reactive centre loop completes a b-hairpin turn
and so occludes the compound binding site.
GSK716 blocks Z a1-antitrypsin polymerisation in cell-free media
and in the ER of both CHO and iPSC models of a1-antitrypsin
deficiency. It increased secretion from the iPSC model by approxi-
mately threefold. Treatment with GSK716 reduced the levels of
intracellular Z a1-antitrypsin polymer compared with cells assessed
before compound addition demonstrating that polymers can be
cleared over the time course of the experiment and that accumula-
tion of polymers is reversible in ZZ-iPSC-hepatocytes. These find-
ings were confirmed by pulse-chase experiments which showed that
GSK716 abolished intracellular polymers (when assessed by the 2C1
mAb) and increased the clearance and secretion of Z a1-antitrypsin.
Dosing of GSK716 in transgenic mice that express Z a1-antitrypsin
increased circulating levels of Z a1-antitrypsin by sevenfold within
3 days, indicating robust target engagement. This effect was main-
tained to the conclusion of the experiment at day 21. The increase
in Z a1-antitrypsin in the circulation at 10 and 30 mg/kg of GSK716
was surprising given that systemic free drug levels were below the
cellular EC50 for secretion for much or all of the dosing period. The
reason for this is unclear but it is possible that the target engage-
ment in vivo is greater than predicted from the potency in the
in vitro cellular assays. Alternatively, it is possible that the first-pass
effect of drug reaching the liver immediately after absorption deliv-
ers some efficacy over that predicted from modelling the compound
concentration at steady-state levels. Together, these data suggest
potential upsides for the required compound exposure to deliver
efficacy in individuals with Z a1-antitrypsin deficiency.
Despite the increase in plasma levels of Z a1-antitrypsin, there
was no reduction in intrahepatic Z a1-antitrypsin inclusions after
20 days of dosing in the transgenic mouse. This may be because the
Z a1-antitrypsin is released from the globule-devoid hepatocytes or
because the intrahepatic polymers in the transgenic mice are not
cleared as readily as those that are generated over a few days in
model systems such as CHO cells and iPSC hepatocytes. Our find-
ings are in contrast to work with the autophagy activator carba-
mazepine which had profound effects on liver polymer in Z a1-
antitrypsin transgenic mice following 2 weeks of dosing (Hidvegi
et al, 2010). RNAi approaches that inhibit Z a1-antitrypsin expres-
sion and polymer formation have reported decreases in Z a1-antit-
rypsin in transgenic mouse liver following 12–33 weeks of
treatment, albeit without reports of data at earlier timepoints (Guo
et al, 2014). It is likely that GSK716 will need to be dosed to
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transgenic Z a1-antitrypsin mice for significantly longer than
20 days to demonstrate an effect on total liver polymer levels. It
remains to be seen whether the intrahepatic polymer needs to be
cleared from the liver in order to have some functional benefit or
whether the accumulated polymer inclusions are inert and abroga-
tion of polymer production is sufficient to restore the functioning of
the ER and hence the health of the cells. Moreover, treatment with
GSK716 may be sufficient to protect against the two-hit process
A B I II
III IV
C
Figure 6. GSK716 increases secretion of Z a1-antitrypsin in a transgenic mouse model of Z a1-antitrypsin deficiency.
Z a1-antitrypsin transgenic animals were dosed with 10, 30 or 100 mg/kg GSK716 three times a day. Total concentrations of GSK716 were determined by LC-MS/MS
(Table 2)
A 100 mg/kg GSK716 resulted in a mean sevenfold increase in circulating monomeric Z a1-antitrypsin levels demonstrating robust target engagement in the liver. The
observed steady-state total and free compound levels of GSK716 in the transgenic Z a1-antitrypsin mouse were well-predicted by the in silico PK model built on: (i)
in vitro metabolic clearance data, (ii) plasma protein binding data, (iii) in vivo PK data from wild-type mice and (iv) a term comprising a 5 lM circulating sink for drug
with an affinity of 1.5 nM, representing the Z a1-antitrypsin within blood. The target-free drug concentration was selected based on the observed potency in the
in vitro secretion assays in which the total drug approximates to the free drug in the assay. Interestingly, 30 mg/kg and 10 mg/kg groups also gave significant, dose-
dependent increases in circulating Z a1-antitrypsin despite free concentrations being below the cellular EC50 for secretion for much or all of the dosing period.
Significance at P < 0.05 by a Student t-test is denoted by *, shown as pairwise comparisons (each animal is compared with itself, treated vs pre-treatment) and
between groups (compound treated vs vehicle), with n = 7, 8 and 8 per group for day 6 dose level 10, 30 and 100 mg/Kg, respectively; day 15, n = 10; day 21, n = 5.
Data presented as mean  SD.
B Representative example images of 2C1-stained livers from a 20-day vehicle (i and ii) and 100 mg/kg TID GSK716 (iii and iv)-treated animals. The asterisks indicate
regions of hepatocytes that are negative on 2C1 immunostaining. Scale bar (i) and (iii) 2mm and (ii) and (iv) 100 µm.
C Quantification of 2C1 stained area in livers from vehicle and 100 mg/kg TID GSK716-treated animals at day 15 (top) and 21 (bottom), shown as total area and low-
only or high and mid-only intensity-stained areas. There were no significant differences between groups by Mann–Whitney U-test; graphs show
median  interquartile ranges, with n = 5 per group.
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whereby the Z a1-antitrypsin polymers sensitise the liver to a
secondary insult such as alcohol, drug or liver fat (Ordo~nez et al,
2013; Strnad et al, 2019).
Polymer formation and inhibitory activity are inextricably linked
in the serpin mechanism (Gooptu & Lomas, 2009), and thus, small
molecules that block polymerisation may have the unwanted effect
of also blocking inhibitory activity. Bound GSK716 inhibits the
serpin activity of a1-antitrypsin and so would not be expected to
increase protease inhibitory activity during the dosing period.
However, the half-life of monomeric Z-a1-antitrypsin in humans is
~ 6 days whereas the drug would be expected to be cleared with a
half-life of a few hours after dosing, raising the possibility of a
pulsatile dosing regimen that would lead to increased, active serpin.
The slow development of the lung disease in individuals with a1-
antitrypsin deficiency over many decades suggests that acute effects
associated with inhibition of serpin activity are unlikely.
There is increasing recognition that heterozygosity for wild-type
M and mutant Z a1-antitrypsin alleles predisposes to liver disease
(Strnad et al, 2019). Our small molecule approach to block polymer
formation has an advantage over siRNA therapies to “knockdown”
a1-antitrypsin production in treating the MZ a1-antitrypsin heterozy-
gote. GSK716 has a 100-fold greater affinity for Z than M a1-antit-
rypsin and so may be dosed at a level that prevents polymerisation
of Z a1-antitrypsin without reducing the inhibitory effect of the wild-
type M protein.
In summary, we report the first small molecule drug-like correc-
tors of Z a1-antitrypsin folding obtained via optimisation of hits
from an encoded library technology screen (Clark et al, 2009; Arico-
Muendel, 2016; Goodnow et al, 2017) that are suitable for oral deliv-
ery, correct folding in human patient iPSC-derived hepatocytes and
increase circulating Z a1-antitrypsin levels in a transgenic mouse
model of a1-antitrypsin deficiency.
Materials and Methods
Alpha1-antitrypsin was purified from the plasma of M (wild-type)
and Z a1-antitrypsin homozygotes, and recombinant Cys232Ser a1-
antitrypsin was expressed and purified as detailed previously
(Lomas et al, 1993; Irving et al, 2011; Haq et al, 2013). The data
generated in this manuscript have used a number of different prepa-
rations of GSK716 all of which have been checked for identity and
purity by NMR/MS. Moreover, all batches have been tested for
activity in blocking a1-antitrypsin polymerisation in the assay as
shown in Fig 1B. Full experimental procedures and analytical data
for synthesising GSK716 are available in patent WO2019/243841A1
(“compound 1”). The experiments conformed to the principles set
out in the WMA Declaration of Helsinki and the Department of
Health and Human Services Belmont Report. All animal studies
were ethically reviewed and carried out in accordance with Euro-
pean Directive 2010/63/EEC and the GSK Policy on the Care,
Welfare and Treatment of Animals, or by the ethical review process
at the institution where the work was performed.
DNA-encoded library technology screen
An encoded library technology (ELT) screen with a nominal diver-
sity of 2 × 1012 unique components was used to identify small
molecules that bind monomeric Z a1-antitrypsin at 4, 22 and 37°C.
Affinity selections were performed as described previously (Clark
et al, 2009).
In vitro assay of Z a1-antitrypsin polymerisation
An antibody-based time-resolved fluorescence resonance energy
transfer (TR-FRET) assay was developed to monitor the polymeri-
sation of 5 nM Z a1-antitrypsin following incubation with varying
concentrations of compounds at 37°C for 72 h. This assay used
the 2C1 monoclonal antibody (1.25 nM) that is specific to
pathological polymers of a1-antitrypsin (Miranda et al, 2010), a
polyclonal antibody (1/320 dilution) that binds to all forms of a1-
antitrypsin (Abcam product 9373), an anti-mouse IgG (1.5 nM)
labelled with fluorescence donor Eu-W1024 (Perkin Elmer product
AD0076) and an anti-rabbit IgG (14.3 nM labelled with acceptor
[APC]). In the presence of polymeric Z a1-antitrypsin, a 4-anti-
body sandwich is formed allowing energy transfer to occur
between the Europium- and Allophycocyanin fluorophores. The
TR-FRET signal was read on an Envision plate reader (Perki-
nElmer), by excitation of Europium at 337 nm and detection of
emission at 665 and 620 nm.
Compound association experiments
Kinetic parameters of GSK716 binding to M, Z, S (Glu264Val) and
Baghdad (Ala336Pro) (Haq et al, 2016) a1-antitrypsin were
measured by detecting intrinsic tryptophan fluorescence of the
protein (excitation at 280 nm and detection of emission at 320 nm)
on a stopped flow apparatus (Applied Photophysics) (Kim & Yu,
1996; Dafforn et al, 1999). A competition assay for binding to M a1-
antitrypsin and Z a1-antitrypsin and Z a1-antitrypsin polymers
(Lomas et al, 1993; Irving et al, 2011; Haq et al, 2013), based on an
Alexa488-labelled analogue of GSK716 (A488-GSK716), was used to
determine the binding affinity of test compounds.
Thermal stability, unfolding and assessment of protease
inhibition
The native state stability of a1-antitrypsin on addition of
compounds was investigated by thermal denaturation in the pres-
ence of a 5X concentration of SYPRO Orange dye solution (Life
Technologies) (Nettleship et al, 2008). Resistance to heat-induced
polymerisation was determined using an end-point constant-
temperature assay. Equilibrium unfolding was evaluated with a
bis-ANS dye (Dafforn et al, 1999), and rapid refolding follow-
ing denaturation in 6 M urea was assessed by non-denaturing
PAGE. The inhibitory activity of a1-antitrypsin was measured by
titration against the model protease bovine a-chymotrypsin. The
activity of antithrombin, neuroserpin and a1-antichymotrypsin
was assessed against human thrombin, bovine trypsin and bovine
a-chymotrypsin, respectively.
Crystallisation and structure determination
Crystallisation of recombinant Cys232Ser a1-antitrypsin was carried
out in 2-well MRC crystallisation plates with a Mosquito robot (TTP
Labtech) using 100 nl protein solution and 100 nl well solution.
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Crystals grew from 22% w/v PEG1500, 0.2 M MES pH6.0 and were
soaked for 24 h with 25 mM compound (5% v/v DMSO). X-ray
diffraction data were collected at Diamond on beamline I03. Struc-
ture solution was carried out by molecular replacement using
PHASER (McCoy et al, 2007). The model used to solve this structure
was a related complex (data not shown) which had been solved by
molecular replacement using PDB entry 2QUG as a starting model.
Building was carried out using Coot (Emsley et al, 2010) and refine-
ment with REFMAC (Murshudov et al, 1997).
In vitro pharmacokinetics
ChromLogD was measured as previously described (Valko
et al, 1997).
Permeability in MDR1-MDCK cells with pgp inhibitor
MDR1-MDCK cells were used between passage numbers 6–30. Cells
were seeded onto Millipore Multiscreen Transwell plates at
3.4 × 105 cells/cm2. The cells were cultured in DMEM and media
was changed on day 3. On day 4 the permeability study was
performed. Cell culture and assay incubations were carried out at
37°C in an atmosphere of 5% v/v CO2 with a relative humidity of
95%. On the day of the assay, the monolayers were prepared by
rinsing both apical and basolateral surfaces twice with Hanks
Balanced Salt Solution (HBSS) at the desired pH warmed to 37°C.
Cells were then incubated with HBSS at the desired pH in both
apical and basolateral compartments for 40 min to stabilise physio-
logical parameters. Where applicable, a P-gp inhibitor (elacridar,
2 µM) was included on both sides of the monolayer for the equili-
bration period. For assessment of apical-basolateral permeability,
HBSS was removed from the apical compartment and replaced with
test compound dosing solution. The apical compartment insert was
then placed into a companion plate containing fresh buffer (contain-
ing 0.5% v/v DMSO or, where applicable, a P-gp inhibitor, main-
taining a 0.5% v/v DMSO concentration). For assessment
of basolateral-apical permeability, HBSS was removed from the
companion plate and replaced with test compound dosing solution.
Fresh buffer (containing 0.5% v/v DMSO or, where applicable, a P-
gp inhibitor, maintaining a 0.5% v/v DMSO concentration) was
added to the apical compartment insert, which was then placed into
the companion plate. At 60 min the apical compartment inserts and
the companion plates were separated and apical and basolateral
samples diluted for analysis.
CYP3A4 TDI fold IC50 shift
Seven concentrations of GSK716 (2, 4, 10, 20, 40, 100 and 200 µM)
plus a vehicle control (0.25% v/v DMSO in pre-incubation) were
pre-incubated at 37°C with human liver microsomes (0.1 mg/ml)
and NADPH (1 mM) for a range of five pre-incubation times (5, 10,
15, 20 and 30 min) with a 0 min pre-incubation, in duplicate. At the
end of the individual pre-incubations, an aliquot of the pre-incuba-
tion mixture was added to an incubation mixture in a 1:20 dilution
for GSK716 with the specific CYP3A4 probe substrate, midazolam
(12.5 µM, equivalent to 5xKm44) and NADPH (1 mM) for a 5 min.
The reactions were terminated by transferring an aliquot of incuba-
tion mixture to methanol. The samples were mixed and then centri-
fuged at 2,500 rpm for 30 min at 4°C. Aliquots of the supernatant
were diluted with formic acid (final concentration 0.1 % v/v) in
deionised water containing internal standard (metoprolol; final
concentration 0.03 mg/l). Samples were analysed by LC-MS/MS.
Hepatocyte clearance
Williams E media supplemented with 2 mM L-glutamine and 25 mM
HEPES and test compound (final compound concentration 0.5 µM;
final DMSO concentration 0.25% v/v) were preincubated at 37°C prior
to the addition of a suspension of cryopreserved pooled hepatocytes
(final cell density 0.5 × 106 viable cells/ml) to initiate the reaction.
The final incubation volume was 500 µl. The reactions were stopped
by transferring 50 µl of incubate to 100 µl acetonitrile containing
internal standard at the appropriate time points (0, 5, 10, 20, 40 and
60 min, 0, 10, 20, 40, 60 and 120 min or 0, 20, 40, 60, 120 and
240 min). The control (lysed cells or vehicle) was incubated for 60,
120 or 240 min only. The termination plates were centrifuged at
2,500 rpm at 4°C for 30 min to precipitate the protein. Following
protein precipitation, the sample supernatants were analysed by
LC-MS/MS. From a plot of loge peak area ratio (compound peak area/
internal standard peak area) against time, the gradient of the line
was determined and half-life (t½) and intrinsic clearance (CLint)
were calculated.
Measurement of monomeric Z a1-antitrypsin in plasma and
cell biology
Plasma standards of monomeric and polymeric Z a1-antitrypsin
were prepared and assayed with an antibody mix comprising a
1:160 dilution of rabbit polyclonal anti- a1-antitrypsin (Abcam
product 9373), 0.23 µg/ml terbium anti-mouse, 4.5 µg/ml Alexa488
goat anti-rabbit, 0.17 µg/ml mouse anti-total- a1-antitrypsin mono-
clonal 3C11 and 2 µg/ml mouse 2C1 anti-polymeric- a1-antitrypsin.
After a 16-h incubation at 20°C, TR-FRET detection was performed
on an Envision plate reader (Perkin Elmer).
Plots of the FRET ratio (acceptor/donor signal) versus sample
dilution result in bell-shaped curves due to the hook effect. The
polymer Z a1-antitrypsin concentration was determined by compar-
ing the peak positions of these bell-shaped curves for plasma
samples with those for polymer calibration samples. The polymer
concentration in the plasma sample and the polymer calibration curve
was then used to derive the contribution of polymer to the FRET
signal in the total a1-antitrypsin assay at the signal peak, enabling
determination of the concentration of monomeric Z a1-antitrypsin.
Z a1-antitrypsin secretion / polymerisation in
CHO-TET-ON-Z-a1AT cells
The accumulation and clearance of Z a1-antitrypsin polymer was
measured with the 2C1 monoclonal antibody that is specific for
polymerised antitrypsin in CHO-TET-ON-Z-a1AT cells (Ordo~nez
et al, 2013) and iPSC-derived hepatocytes generated from a patient
with a PiZZ genotype (Yusa et al, 2011). Secretion of Z a1-antit-
rypsin was determined by TR-FRET. Cell viability was analysed with
Cell Counting Kit-8 (Sigma) after treating the cells with 10 µM
GSK716 or 0.1% v/v DMSO (vehicle) and an increasing concentra-
tion of tunicamycin (0.8–0.01 µg/ml).
Pulse chase experiments
CHO K1 cells were labelled after 48-h induction with 0.5 lg/ml
doxycycline. Cells were pulsed (0.45 MBq/106 cells) for 10 min with
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35S Cys/Met (EasyTagTM Express Protein Labelling, Perkin Elmer,
Beaconsfield, UK) in DMEM without Cys/Met, and then chased in
normal culture medium for 0, 1, 4, 8 and 12 h. Radiolabelled a1-
antitrypsin was isolated by immunoprecipitation and resolved by
SDS–PAGE followed by autoradiography. Densitometric analysis of
a1-antitrypsin bands was performed with ImageStudioLite (LI-COR
Biosciences, USA). Statistical analysis was performed using the
GraphPad Prism program (GraphPad Software, La Jolla, CA, USA).
In vivo experiments
Pharmacokinetics
Male CD-1 mice, Han Wistar rats or beagle dogs were administered
GSK716 as a suspension in 1% w/v aqueous methylcellulose via
oral gavage at doses of 1 mg/kg (dog) or 10, 30 and 100 mg/kg
(mouse, rat). Blood samples were taken into EDTA, diluted and
mixed with acetonitrile containing internal standard (alprazolam)
and centrifuged to precipitate proteins. Aliquots of the resultant
supernatant were analysed by LC-MS/MS, and concentrations of
GSK716 in blood were determined. Non-compartmental pharma-
cokinetic analysis (NCA) was carried out using Phoenix WinNonLin
6.3 (Certara L.P.). Free drug was measured in Z a1-antitrypsin
transgenic mice by dialysing tissue samples in rapid equilibrium
dialysis cassettes.
Z a1-antitrypsin transgenic mouse experiments
Hemizygous female Z a1-antitrypsin transgenic mice were 13–
15 weeks of age at start of study. Drugs were administered via oral
gavage three times a day at 8-h intervals at 10 ml/Kg as a suspen-
sion in aqueous methylcellulose containing 0.5% w/v Tween 80. In
life, blood sampling was performed vial tail nick. Animals were
housed in licensed, approved housing in the UK with appropriate
enrichment. Animals were randomly assigned to groups using
manual methods. Histopathology analysis was performed blind.
Histopathology, immunohistochemistry and image analysis
Formalin-fixed, paraffin-embedded livers from all mice were
sectioned and stained with haematoxylin and eosin (H&E) and
periodic acid Schiff (PAS) with diastase to examine tissue quality
and the presence of diastase-resistant polymer inclusions, respec-
tively. Immunohistochemistry for polymerised a1-antitrypsin was
performed using 2C1 monoclonal primary antibody and a Mouse-
on-Mouse Polymer Kit (Abcam AB127055) for detection. Represen-
tative sections of liver from each mouse were blindly evaluated by
a Board-Certified Veterinary Pathologist and ranked in order of
polymer content. A semi-automated image analysis solution was
developed to quantify total polymer content (Fig EV1). Thresholds
were optimised to separate staining of the polymer inclusions
(high and medium intensity) and more diffuse cytoplasmic staining
(low intensity).
Statistics
Formal power calculations were not performed for in vivo studies
but n numbers were determined based on prior experience with the
model and readout. Animals were randomly assigned to groups,
using manual methods not randomisation tools. In vivo work was
performed by individuals unfamiliar with the project, and ex vivo
analysis was performed by different scientists to those executing the
in life phase. Histopathology analysis was performed blinded.
Data availability
The data set produced in this study: alpha 1-antitrypsin (C232S)
complexed with GSK716 is available in the PDB identifier 7AEL
(http://www.rcsb.org/pdb/explore/explore.do?structureId=7AEL).
Expanded View for this article is available online.
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The paper explained
Problem
Intracellular protein aggregation can result in “gain-of-function” cell
toxicity. It has proved challenging to develop small molecules that
can stabilise intracellular mutant proteins, prevent self-aggregation
and so ameliorate disease. Severe a1-antitrypsin deficiency results
largely from the Z allele (Glu342Lys) that causes the accumulation of
homopolymers of mutant a1-antitrypsin within the endoplasmic retic-
ulum of hepatocytes in association with liver disease.
Results
We have undertaken a medicinal chemistry campaign to develop an
orally bioavailable small molecule that binds to intra-endoplasmic
reticulum mutant Z a1-antitrypsin, corrects the folding defect and
increases secretion in a transgenic model of disease.
Impact
This study reports the successful targeting of an aggregation-prone
mutant in order to prevent the intracellular polymerisation and accu-
mulation of a1-antitrypsin that underlies a1-antitrypsin deficiency. It
demonstrates that “mutation ameliorating” small molecules can block
the aberrant polymerisation that underlies Z a1-antitrypsin deficiency.
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